Who owns DRUGS MADE IN AMER ACQUTN CO?
- Ticker: DMAA
- CUSIP Number: g2847j104
Tip: Access positions for across all investors
Analyze quarterly positions in Drugs Made In Amer Acqutn with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Drugs Made In Amer Acqutn stock
Who bought or sold DRUGS MADE IN AMER ACQUTN CO this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Karpus Investment Management | 2.5M | $26M | 0% | Dec 2025 |
|
| Vivaldi Asset Management | 2.2M | $23M | 0% | Dec 2025 |
|
| Mizuho Securities Usa | 2.0M | $21M | 40% | Mar 2026 |
|
| Glazer Capital | 1.7M | $18M | -8% | Mar 2026 |
|
| Westchester Capital Management | 1.7M | $18M | 0% | Mar 2026 |
|
| Polar Securities | 1.6M | $17M | 0% | Mar 2026 |
|
| Wolverine Asset Management | 1.6M | $16M | 19% | Mar 2026 |
|
| Jpmorgan Chase & Co | 1.3M | $14M | 1227% | Mar 2026 |
|
| Aristeia Capital | 882k | $9.2M | 0% | Mar 2026 |
|
| D. E. Shaw & Co | 690k | $7.2M | 0% | Mar 2026 |
|
| Heights Capital Management | 650k | $6.7M | 0% | Dec 2025 |
|
| Shaolin Capital Management | 550k | $5.8M | 172% | Mar 2026 |
|
| Radcliffe Capital Management | 547k | $5.7M | 4% | Dec 2025 |
|
| LMR Partners | 500k | $5.2M | 0% | Mar 2026 |
|
| J. Goldman & Co | 500k | $5.2M | 0% | Dec 2025 |
|
| Rivernorth Capital Management | 418k | $4.4M | 0% | Mar 2026 |
|
| Whitebox Advisors | 400k | $4.2M | 0% | Mar 2026 |
|
| Meteora Capital | 380k | $4.0M | 100% | Mar 2026 |
|
| CNH Partners | 358k | $3.8M | -4% | Mar 2026 |
|
| Clear Street Group | 354k | $1.3M | 100% | Mar 2026 |
|
| RLH Capital | 317k | $3.3M | 100% | Mar 2026 |
|
| Hudson Bay Capital Management | 298k | $3.1M | -81% | Mar 2026 |
|
| Quarry | 267k | $2.8M | 1596% | Dec 2025 |
|
| Context Capital Management | 250k | $2.6M | 0% | Mar 2026 |
|
| Governors Lane | 250k | $2.6M | 2132% | Dec 2025 |
|
| Toronto-Dominion Bank | 204k | $2.1M | -55% | Mar 2026 |
|
| Sona Asset Management | 163k | $1.7M | 100% | Mar 2026 |
|
| Goldman Sachs Group | 120k | $1.3M | 0% | Mar 2026 |
|
| DLD Asset Management | 101k | $1.1M | 0% | Mar 2026 |
|
| Warberg Asset Management | 92k | $966k | 0% | Mar 2026 |
|
| Geode Capital Management | 62k | $654k | 36% | Mar 2026 |
|
| Periscope Capital | 50k | $525k | 0% | Mar 2026 |
|
| Oakmont Partners | 36k | $382k | 0% | Mar 2026 |
|
| Lineage Point Capital | 32k | $334k | 0% | Mar 2026 |
|
| Hrt Financial | 28k | $288k | -3% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 15k | $154k | 100% | Mar 2026 |
|
| Citadel Advisors | 11k | $110k | 100% | Mar 2026 |
|
| Morgan Stanley | 58.00 | $608.002400 | -52% | Mar 2026 |
|
Who sold out of Drugs Made In Amer Acqutn?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Mercuria Capital Strategies | Dec 2025 | 750k | $7.5M |
| Boothbay Fund Management | Dec 2025 | 346k | $3.6M |
| Brooklyn Capital Management | Dec 2025 | 130k | $1.4M |
| UBS Group | Dec 2025 | 38k | $396k |
| Sandia Investment Management | Sep 2025 | 16k | $162k |
| Logan Stone Capital | Dec 2025 | 11k | $113k |